Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 1 (1)

Trial Status

Recruiting1
Active Not Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT04092270Phase 1Active Not RecruitingPrimary

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT07062016Recruiting

Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

Showing all 2 trials

Research Network

Activity Timeline